Synthetic Biology Platforms
Inari Agriculture
by Inari Agriculture, Inc.
Gene editing and predictive design platform creating multiplexed trait improvements in seeds to feed a growing planet
Category
Synthetic Biology Platforms
Founded
2016
Headquarters
Cambridge, MA, USA
Overview
Inari Agriculture applies multiplex gene editing and AI-driven predictive design to create next-generation seeds with simultaneously improved traits — yield, drought tolerance, nitrogen use efficiency, and disease resistance — without the time and cost of conventional breeding or transgenic approaches. The company's SEEDesign platform combines CRISPR-based multiplex editing of elite germplasm with computational models of plant genetics to predict which combinations of edits will produce the most valuable phenotypic improvements in farmers' fields. Working with partners in corn, soybean, and wheat, Inari applies its platform to introduce multiple simultaneous edits across the same germplasm, compressing the timeline from trait concept to commercial variety from 10-15 years in conventional breeding to 3-5 years. Because the company's approach uses gene editing rather than transgenic modification, its products may qualify for reduced regulatory oversight compared to GMO crops in many jurisdictions, enabling faster market entry. Inari's differentiation is its multiplex editing capability combined with predictive genomics — while most agricultural gene editing companies introduce one or two edits, Inari's platform enables 5-10 simultaneous edits per variety, creating multi-trait improvements impossible with single-edit approaches. The company has raised over $290 million from investors including Flagship Pioneering and has established partnerships with major seed companies seeking to deploy the SEEDesign platform on commercial germplasm.
Key Features
Organism Tracking & IP
Track engineered organisms with digital provenance records and intellectual property documentation.
Automated Strain Engineering
High-throughput strain construction combining robotic assembly with ML-guided genetic design.
Metabolic Pathway Design
Computational design of biosynthetic pathways for production of target compounds in engineered organisms.
Design-Build-Test-Learn Automation
Automated DBTL cycle with integrated data capture and machine learning optimization.
Genetic Parts Catalog
Curated libraries of characterized genetic parts including promoters, terminators, and regulatory elements.
Pros & Cons
Pros
- +Metabolic modeling predicts optimal genetic modifications for target compound production
- +Proprietary strain libraries and genetic parts catalogs accelerate design-build-test-learn cycles
- +Bio-manufacturing partnerships enable commercial scale-up from prototype to production organisms
- +Foundry-scale automation processes thousands of genetic designs in parallel
- +Cell programming platform designs custom organisms for therapeutics, agriculture, and industrial biotechnology
- +Automated organism engineering combines high-throughput strain construction with ML-guided design
- +End-to-end platform from DNA design through fermentation optimization and process development
Cons
- −Intellectual property landscape for genetic parts and engineered organisms is complex
- −Regulatory frameworks for engineered organisms vary globally and can delay commercialization
- −Scale-up from laboratory to commercial production introduces unpredictable biological challenges
- −Design-build-test-learn cycles still require weeks to months for complex organism engineering
Use Cases
Strain Engineering & Optimization
Automated organism engineering combining high-throughput strain construction with ML-guided metabolic design.
Biosynthetic Pathway Design
Computational design of metabolic pathways for production of target compounds in engineered organisms.
Fermentation Scale-Up
Data-driven optimization of fermentation conditions from lab-scale to commercial biomanufacturing.